{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Armandi A"],"funding":["Gilead Sciences (Italy)"],"pagination":["650"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9862059"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["<b>Background and aims:</b> Non-invasive tests (NITs) are needed in clinical practice to replace histology for the identification of liver fibrosis and prognostication in Non-Alcoholic Fatty Liver Disease (NAFLD). Novel collagen-derived fibrogenesis markers including N-terminal type III collagen pro-peptide (PRO-C3) are among the most promising tools in this field. The aim of this study was to assess the diagnostic accuracy of PRO-C3, the derivative ADAPT score, and other NITs for the identification of advanced fibrosis (stages 3-4) and changes over 12 months of follow-up. <b>Methods:</b> In this longitudinal study, 96 patients with biopsy-proven NAFLD were evaluated at baseline, of which 50 underwent a follow-up visit after 12 months. Clinical-biochemical parameters, liver stiffness (LS) by transient elastography, PRO-C3, and other NITs (ADAPT, FIB-4, NFS, APRI) were collected at baseline and follow-up. <b>Results:</b> LS showed the best accuracy for the identification of advanced fibrosis, with Area under the Receiving Operator Curve (AUROC) 0.82 (0.73-0.89) for a cut-off value of 9.4 kPa. Among the other NITs, the ADAPT score showed the best accuracy, with AUROC 0.80 (0.71-0.88) for a cut-off of 5.02 (Se 62%, Sp 89%, PPV 74%, NPV 83%). The comparison between the AUROC of LS with that of ADAPT was not statistically different (DeLong test <i>p</i> value 0.348). At follow-up, LS was slightly reduced, whilst PRO-C3 displayed a significant increase from baseline median 11.2 ng/mL to 13.9 ng/mL at follow-up (<i>p</i> = 0.017). Accordingly, ADAPT score increased from median 5.3 to 6.1 (<i>p</i> = 0.019). The other NITs did not significantly change over 12 months. <b>Conclusions:</b> The ADAPT score shows the best performance among non-invasive scores for the identification of advanced fibrosis, not different from LS. Collagen-derived biomarker PRO-C3 and the derivative score ADAPT display significant changes over time, and may be useful tools for monitoring the progression of liver disease or assessing responses to treatments."],"journal":["Journal of clinical medicine"],"pubmed_title":["Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease."],"pmcid":["PMC9862059"],"funding_grant_id":["Fellowship 2019"],"pubmed_authors":["Saracco GM","Rosso C","Castelnuovo G","Perez-Diaz-Del-Campo N","D'Amato D","Karsdal MA","Caviglia GP","Younes R","Leeming DJ","Nicolosi A","Abdulle A","Armandi A","Ribaldone DG","Bugianesi E"],"additional_accession":[]},"is_claimable":false,"name":"Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.","description":"<b>Background and aims:</b> Non-invasive tests (NITs) are needed in clinical practice to replace histology for the identification of liver fibrosis and prognostication in Non-Alcoholic Fatty Liver Disease (NAFLD). Novel collagen-derived fibrogenesis markers including N-terminal type III collagen pro-peptide (PRO-C3) are among the most promising tools in this field. The aim of this study was to assess the diagnostic accuracy of PRO-C3, the derivative ADAPT score, and other NITs for the identification of advanced fibrosis (stages 3-4) and changes over 12 months of follow-up. <b>Methods:</b> In this longitudinal study, 96 patients with biopsy-proven NAFLD were evaluated at baseline, of which 50 underwent a follow-up visit after 12 months. Clinical-biochemical parameters, liver stiffness (LS) by transient elastography, PRO-C3, and other NITs (ADAPT, FIB-4, NFS, APRI) were collected at baseline and follow-up. <b>Results:</b> LS showed the best accuracy for the identification of advanced fibrosis, with Area under the Receiving Operator Curve (AUROC) 0.82 (0.73-0.89) for a cut-off value of 9.4 kPa. Among the other NITs, the ADAPT score showed the best accuracy, with AUROC 0.80 (0.71-0.88) for a cut-off of 5.02 (Se 62%, Sp 89%, PPV 74%, NPV 83%). The comparison between the AUROC of LS with that of ADAPT was not statistically different (DeLong test <i>p</i> value 0.348). At follow-up, LS was slightly reduced, whilst PRO-C3 displayed a significant increase from baseline median 11.2 ng/mL to 13.9 ng/mL at follow-up (<i>p</i> = 0.017). Accordingly, ADAPT score increased from median 5.3 to 6.1 (<i>p</i> = 0.019). The other NITs did not significantly change over 12 months. <b>Conclusions:</b> The ADAPT score shows the best performance among non-invasive scores for the identification of advanced fibrosis, not different from LS. Collagen-derived biomarker PRO-C3 and the derivative score ADAPT display significant changes over time, and may be useful tools for monitoring the progression of liver disease or assessing responses to treatments.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2024-11-21T01:03:44.569Z","creation":"2024-11-21T01:03:44.569Z"},"accession":"S-EPMC9862059","cross_references":{"pubmed":["36675579"],"doi":["10.3390/jcm12020650"]}}